A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).

Study Overview

• Status: Completed
• Conditions: Hidradenitis Suppurativa
• Intervention / Treatment: Drug: INCB054707

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90045
      • Investigative Site
  • Florida
    • Tampa, Florida, United States, 33624
      • Investigative Site
  • New York
    • New York, New York, United States, 10065
      • Investigative Site
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.
• Stable course of HS for at least 90 days before screening, as determined by the investigator.
• HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley Stage II or III at screening and baseline.
• Total AN count of at least 3 at screening and baseline.
• Male participants must agree to use contraception per protocol-defined criteria.

Exclusion Criteria:

• Women of childbearing potential or who are currently pregnant or lactating.
• Presence of > 20 draining fistulas at screening and baseline.

• Participants with concurrent conditions or history of other diseases as follows:

  • Any clinically significant medical condition other than HS, as determined by the investigator, that is not adequately controlled with appropriate treatment.
  • Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with the course, severity, or assessments of HS.
  • Active systemic viral infection or any active viral infection that, based on the investigator's clinical assessment, make the participant an unsuitable candidate for the study.
  • Current herpes zoster infection, a history of recurrent herpes zoster, a history of disseminated herpes simplex, or a history of herpes zoster.
  • History of malignancy, including lymphoma and leukemia within 5 years before baseline, other than a successfully treated nonmetastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix.
  • Albinism.
• Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF), defined as ≥ 450 msec.
• Positive test result for tuberculosis (TB) from the QuantiFERON-TB Gold test, or equivalent, at screening (or, if 2 indeterminate tests or not available, then as evaluated by a purified protein derivative test with a result of < 5 mm of induration within 3 months of screening) or a history of active TB.
• Positive serology test results for HIV, HBsAg, hepatitis B virus (HBV) core antibody, or HCV (HCV antibody with positive HCV-RNA) at screening.
• Decreased blood cell counts at screening as per protocol-defined parameters.
• Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥ 1.5 × upper limit of normal (ULN).
• Impaired renal function with serum creatinine > 1.5 mg/dL.
• Use of prohibited medications per protocol-defined criteria.
• Known or suspected allergy to INCB054707 or any component of the study drug.
• Known history of clinically significant drug or alcohol abuse in the last year prior to baseline.
• Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: INCB054707	Drug: INCB054707; INCB054707 administered once daily orally with water without regard to food for 8 weeks.; Other Names: Povorcitinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment-emergent Adverse Events (TEAEs)	A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.	Up to approximately 12 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Apparent Oral Clearance of INCB054707(CL/F)	To evaluate the systemic exposure to INCB054707.	Postdose Day1, week 2 and 6
Apparent Oral Volume of Distribution of INCB054707(Vc/F)	To evaluate the systemic exposure to INCB054707.	Postdose Day1, week 2 and 6.
Absorption Constant of INCB054707 (Ka)	Other population pharmacokinetic (PK) model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.	Postdose Day1, week 2 and 6.
Apparent Inter-compartmental Clearance(Q/F)	Other population PK model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.	Postdose Day1, week 2 and 6.
Proportion of Participants With a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit	An HiSCR is defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline at each visit.	Weeks 1,2,4,6,8 and FollowUp
Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit	The number and proportion of participants who achieved an Abscess and Inflammatory nodule count of 0 to 2 progressively.	Weeks 1,2,4,6,8 and FollowUp
Mean Change From Baseline in the HS Pain Numeric Rating Scale (NRS) Scores at Each Visit	The HS Pain NRS will be completed in a daily diary by participants from screening through EOS. An 11-point scale will be used to assess the worst skin pain due to HS based on a recall period of the last 24 hours. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine)	Weeks 1,2,4,6,8 and FollowUp
Mean Change From Baseline in the Modified Sartorius Scale Score	The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.	Week 8.
Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit	Draining fistulas are fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.	Up to approximately 12 weeks.
Proportion of Participants at Each Category of Hurley Stage	The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.	Baseline and Week 8.
Proportion of Participants With Change From Baseline to Week 8 in Hurley Stage	The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.	Week 8.
Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category	The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.	Up to approximately 12 weeks.
Proportion of Participants Requiring Rescue Lesional Treatment	Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.	Up to approximately 12 weeks.
Number of Interventions With Rescue Lesional Treatment	Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.	Up to approximately 12 weeks.
Proportion of Participants at Each Scoring Category of the Dermatology Life Quality Index (DLQI) at Each Visit	The DLQI is a questionnaire used to assess the symptoms and the impact of skin problems on quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The meaning of DLQI scores can be categorized as follows: 0-1 = No effect at all on patient's life 2-5 = Small effect on patient's life 6-10 = Moderate effect on patient's life 11-20 = Very large effect on patient's life 21-30 = Extremely large effect on patient's life	Up to approximately 12 weeks.

Collaborators and Investigators

• Sponsor: Incyte Corporation

Publications and helpful links

General Publications

• Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022 May;186(5):803-813. doi: 10.1111/bjd.20969. Epub 2022 Mar 6.

Study record dates

Study Major Dates

• Study Start (Actual): July 17, 2018
• Primary Completion (Actual): April 22, 2019
• Study Completion (Actual): April 22, 2019

Study Registration Dates

• First Submitted: May 24, 2018
• First Submitted That Met QC Criteria: June 22, 2018
• First Posted (Actual): June 26, 2018

Study Record Updates

• Last Update Posted (Actual): September 26, 2022
• Last Update Submitted That Met QC Criteria: September 14, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Hidradenitis suppurativa (HS); Janus kinase (JAK); Janus kinase 1 (JAK1) inhibitor
• Additional Relevant MeSH Terms: Sweat Gland Diseases; Skin Diseases; Infections; Bacterial Infections; Bacterial Infections and Mycoses; Skin Diseases, Infectious; Suppuration; Skin Diseases, Bacterial; Hidradenitis Suppurativa; Hidradenitis
• Other Study ID Numbers: INCB 54707-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No